Melanie M. Taylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melanie M. Taylor has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
Nathalie Broutet
Affiliation Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
7 shared publicationsEline Korenromp
Avenir Health, Geneva, Switzerland
3 shared publications- Eline Louise Korenromp
Data for Impact Department, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland
3 shared publications - Harriet D. Gliddon
London Centre for Nanotechnology, University College London, London, UK
3 shared publications - James Kiarie
Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland
3 shared publications Julia Skinner
Arizona Department of Health Services, STD Program, Phoenix, AZ
3 shared publications
Latest Publications
- 8 June 2026
- Published by SAGE Publications in Public Health Reports®
- Vol. 141 (6) , 773-778
A US Public Health Service Commissioned Corps Response to a Syphilis Outbreak in Tribal Communities in South Dakota and North Dakota, 2025
From January 5 through April 4, 2025, and July 14 through October 10, 2025, the US Public Health Service Commissioned Corps conducted the largest reported deployment in response to a syphilis outbreak in US history. During two 90-day periods, 67 US Public Health Service officers were deployed in 30-day rotations across 9 Tribal areas within the Indian Health Service Great Plains Area and 3 urban centers in South Dakota and North Dakota to support ongoing outbreak activities. Overall, the deployment identified 139 people newly diagnosed with syphilis through screening 2913 people. By 30 days after deployments for the syphilis outbreak response, 126 (90.6%) people with newly diagnosed syphilis had started treatment. This case study highlights the effective coordination among the Indian Health Service, the US Public Health Service Commissioned Corps, state health departments, Tribal health agencies, the Great Plains Tribal Leaders Health Board, and other partners. Prioritized activities of the response included contact tracing, health care provider education, community-based screening events, and field-based administration of treatment. We describe the roles of culturally sensitive public health practice, interagency collaboration, and rapid clinical response in responding to sexually transmitted infection outbreaks. Experience gained in South Dakota and North Dakota may provide insightful direction for future large-scale infectious disease campaigns.
- 8 June 2026
- Published by SAGE Publications in Public Health Reports®
- Vol. 141 (6) , 773-778
A US Public Health Service Commissioned Corps Response to a Syphilis Outbreak in Tribal Communities in South Dakota and North Dakota, 2025
From January 5 through April 4, 2025, and July 14 through October 10, 2025, the US Public Health Service Commissioned Corps conducted the largest reported deployment in response to a syphilis outbreak in US history. During two 90-day periods, 67 US Public Health Service officers were deployed in 30-day rotations across 9 Tribal areas within the Indian Health Service Great Plains Area and 3 urban centers in South Dakota and North Dakota to support ongoing outbreak activities. Overall, the deployment identified 139 people newly diagnosed with syphilis through screening 2913 people. By 30 days after deployments for the syphilis outbreak response, 126 (90.6%) people with newly diagnosed syphilis had started treatment. This case study highlights the effective coordination among the Indian Health Service, the US Public Health Service Commissioned Corps, state health departments, Tribal health agencies, the Great Plains Tribal Leaders Health Board, and other partners. Prioritized activities of the response included contact tracing, health care provider education, community-based screening events, and field-based administration of treatment. We describe the roles of culturally sensitive public health practice, interagency collaboration, and rapid clinical response in responding to sexually transmitted infection outbreaks. Experience gained in South Dakota and North Dakota may provide insightful direction for future large-scale infectious disease campaigns.
- 3 April 2026
- Published by SAGE Publications in Public Health Reports®
- Vol. 141 (5) , 618-621
Reflections on a Tribal–Federal Response to a Syphilis Outbreak
- 3 April 2026
- Published by SAGE Publications in Public Health Reports®
- Vol. 141 (5) , 618-621
Reflections on a Tribal–Federal Response to a Syphilis Outbreak
- Open Access
- 26 March 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (4) , e70091
Progress towards the elimination of vertical transmission of HIV, syphilis and hepatitis B in 21 high‐burden countries
Introduction: Elimination of mother‐to‐child transmission (EMTCT) of HIV, syphilis and hepatitis B by 2030 is a global goal endorsed by countries. To achieve EMTCT, countries need to meet targets for programme and impact indicators. Methods: We examined progress and gaps in service delivery across the three infections among 21 countries with a high burden of HIV, syphilis and/or hepatitis B. We summarized national coverage of interventions to prevent vertical transmission of HIV, hepatitis B and syphilis. Service coverage indicators were extracted from public data sources for the most recent available years (2014−2024). Results: Antenatal care (ANC) coverage (at least one visit) ranged from 62% to 99%; 14 countries (67%) had coverage ≥90%. Twelve countries (57%) had ANC HIV testing coverage above 90%; 13 countries (62%) reported antiretroviral treatment coverage ≥90%. Eight countries (38%) reported ANC syphilis testing coverage ≥90%; ten countries (48%) reported ≥90% treatment coverage among pregnant women diagnosed with syphilis. All 21 countries have introduced three infant doses of hepatitis B vaccine (HepB3), and six countries have introduced the hepatitis B birth dose vaccine (HepB‐BD) in their national immunization schedule. Among the six countries that provide HepB‐BD, only four reported coverage with timely HepB‐BD given within 24 hours of birth (range 52–70%). Seven (33%) countries have achieved HepB3 coverage ≥ 90%. Discussion: Antenatal service delivery for prevention of mother‐to‐child transmission of syphilis and hepatitis B lags behind that of HIV. Despite the availability of ANC platforms for the delivery of HIV, syphilis and hepatitis B services, many countries face new and ongoing implementation and funding challenges in reaching global targets for EMTCT of these infections. Conclusions: Integrating HIV, syphilis and hepatitis B prevention of vertical transmission services into ANC and maintaining support for EMTCT efforts is critical to close these gaps.
- 26 March 2026
- Published by Wiley in Journal of the International AIDS Society
- Vol. 29 (4) , e70091
Open AccessProgress towards the elimination of vertical transmission of HIV, syphilis and hepatitis B in 21 high‐burden countries
Introduction: Elimination of mother‐to‐child transmission (EMTCT) of HIV, syphilis and hepatitis B by 2030 is a global goal endorsed by countries. To achieve EMTCT, countries need to meet targets for programme and impact indicators. Methods: We examined progress and gaps in service delivery across the three infections among 21 countries with a high burden of HIV, syphilis and/or hepatitis B. We summarized national coverage of interventions to prevent vertical transmission of HIV, hepatitis B and syphilis. Service coverage indicators were extracted from public data sources for the most recent available years (2014−2024). Results: Antenatal care (ANC) coverage (at least one visit) ranged from 62% to 99%; 14 countries (67%) had coverage ≥90%. Twelve countries (57%) had ANC HIV testing coverage above 90%; 13 countries (62%) reported antiretroviral treatment coverage ≥90%. Eight countries (38%) reported ANC syphilis testing coverage ≥90%; ten countries (48%) reported ≥90% treatment coverage among pregnant women diagnosed with syphilis. All 21 countries have introduced three infant doses of hepatitis B vaccine (HepB3), and six countries have introduced the hepatitis B birth dose vaccine (HepB‐BD) in their national immunization schedule. Among the six countries that provide HepB‐BD, only four reported coverage with timely HepB‐BD given within 24 hours of birth (range 52–70%). Seven (33%) countries have achieved HepB3 coverage ≥ 90%. Discussion: Antenatal service delivery for prevention of mother‐to‐child transmission of syphilis and hepatitis B lags behind that of HIV. Despite the availability of ANC platforms for the delivery of HIV, syphilis and hepatitis B services, many countries face new and ongoing implementation and funding challenges in reaching global targets for EMTCT of these infections. Conclusions: Integrating HIV, syphilis and hepatitis B prevention of vertical transmission services into ANC and maintaining support for EMTCT efforts is critical to close these gaps.
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 362-371
Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness
Little was known about persistent sequelae of mpox before the 2022 multinational clade II mpox virus outbreak. To characterize post-mpox sequelae 11 to 18 months after acute mpox diagnosis and compare outbreak-associated psychosocial and behavioral impact between at-risk persons who had or did not have mpox. Cohort study. New York City, New York, and Houston, Texas. Adults attending HIV, pre-exposure prophylaxis, or sexually transmitted infection clinics diagnosed with mpox during May 2022 to January 2023 (post-mpox) or at risk for but never diagnosed with mpox (no-mpox). All participants completed psychosocial and behavioral self-assessments. A clinician also assessed post-mpox participants by clinical history and physical examination; persisting mpox physical sequelae were classified by tissue affected and effect on appearance or function. Associations between post-mpox physical sequelae and medical history, acute mpox severity, and sociodemographic characteristics were assessed using marginally adjusted probabilities (presented as risk ratios with 95% CIs). A total of 154 post-mpox and 201 no-mpox participants were enrolled. The proportion of participants reporting increased psychobehavioral symptoms was generally similar between groups. Fifty-eight percent (89 of 154) of post-mpox participants had at least 1 persistent sequelae; 56% (86 of 154) were appearance related, of which 51% (44 of 86) occurred at 2 or fewer sites. Thirteen percent (20 of 154) of post-mpox participants had functional sequelae, of whom 50% (10 of 20) and 35% (7 of 20) had ongoing anorectal and urinary dysfunction, respectively. Participants may not be representative of mpox-affected and susceptible populations. Findings may over- or underestimate frequency or severity of severe mpox sequelae. Post-mpox sequelae frequently persisted 11 to 18 months after acute mpox, with limited body distribution or physical morbidity but with continued social and sexual effects. Centers for Disease Control and Prevention.
- 1 March 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (3) , 362-371
Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness
Little was known about persistent sequelae of mpox before the 2022 multinational clade II mpox virus outbreak. To characterize post-mpox sequelae 11 to 18 months after acute mpox diagnosis and compare outbreak-associated psychosocial and behavioral impact between at-risk persons who had or did not have mpox. Cohort study. New York City, New York, and Houston, Texas. Adults attending HIV, pre-exposure prophylaxis, or sexually transmitted infection clinics diagnosed with mpox during May 2022 to January 2023 (post-mpox) or at risk for but never diagnosed with mpox (no-mpox). All participants completed psychosocial and behavioral self-assessments. A clinician also assessed post-mpox participants by clinical history and physical examination; persisting mpox physical sequelae were classified by tissue affected and effect on appearance or function. Associations between post-mpox physical sequelae and medical history, acute mpox severity, and sociodemographic characteristics were assessed using marginally adjusted probabilities (presented as risk ratios with 95% CIs). A total of 154 post-mpox and 201 no-mpox participants were enrolled. The proportion of participants reporting increased psychobehavioral symptoms was generally similar between groups. Fifty-eight percent (89 of 154) of post-mpox participants had at least 1 persistent sequelae; 56% (86 of 154) were appearance related, of which 51% (44 of 86) occurred at 2 or fewer sites. Thirteen percent (20 of 154) of post-mpox participants had functional sequelae, of whom 50% (10 of 20) and 35% (7 of 20) had ongoing anorectal and urinary dysfunction, respectively. Participants may not be representative of mpox-affected and susceptible populations. Findings may over- or underestimate frequency or severity of severe mpox sequelae. Post-mpox sequelae frequently persisted 11 to 18 months after acute mpox, with limited body distribution or physical morbidity but with continued social and sexual effects. Centers for Disease Control and Prevention.
- 10 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 1984-1992
Applying capture recapture methods to estimate the burden of chlamydial and gonococcal infections using Indian Health Service Medical Records, 2016-2021
American Indian and Alaska Native persons in the United States experience high rates of chlamydia and gonorrhea (CT/GC) infections, but the burden among persons receiving healthcare through the Indian Health Service (IHS) has not been recently described. Currently, there is no surveillance system to regularly monitor IHS-specific CT/GC burden and trends. We used two capture recapture (CRC) methods with two IHS medical records sources: diagnostic codes and laboratory test results linked by person within 30 days among persons ≥15 years during 2016 to 2021. Capture recapture estimates were used with the IHS population to create prevalence rates and compared to the medical records counts. CRC estimated 88 680 (1189 per 100 000) and 83 884 CT infections (1125) and 36 713 (492) and 35 930 GC infections (482). Diagnostic codes were 60% and 63% of CT and 54% and 56% of GC CRC estimates and combined with laboratory test results were 88% and 94% of CT and 86% and 88% of GC CRC estimates. These findings underscore the value of IHS medical records for estimating CT/GC infections and measuring undercounting of single source CT/GC medical records. These sources can be leveraged to provide surveillance estimates for monitoring trends; strategic outreach; and supporting testing, treatment, and staffing needs.
- 10 February 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (7) , 1984-1992
Applying capture recapture methods to estimate the burden of chlamydial and gonococcal infections using Indian Health Service Medical Records, 2016-2021
American Indian and Alaska Native persons in the United States experience high rates of chlamydia and gonorrhea (CT/GC) infections, but the burden among persons receiving healthcare through the Indian Health Service (IHS) has not been recently described. Currently, there is no surveillance system to regularly monitor IHS-specific CT/GC burden and trends. We used two capture recapture (CRC) methods with two IHS medical records sources: diagnostic codes and laboratory test results linked by person within 30 days among persons ≥15 years during 2016 to 2021. Capture recapture estimates were used with the IHS population to create prevalence rates and compared to the medical records counts. CRC estimated 88 680 (1189 per 100 000) and 83 884 CT infections (1125) and 36 713 (492) and 35 930 GC infections (482). Diagnostic codes were 60% and 63% of CT and 54% and 56% of GC CRC estimates and combined with laboratory test results were 88% and 94% of CT and 86% and 88% of GC CRC estimates. These findings underscore the value of IHS medical records for estimating CT/GC infections and measuring undercounting of single source CT/GC medical records. These sources can be leveraged to provide surveillance estimates for monitoring trends; strategic outreach; and supporting testing, treatment, and staffing needs.
- 10 July 2025
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (12) , 775-779
Incentivized Community-Based Syphilis Screening: Uptake, Yield, and Cost
Background: High and increasing syphilis rates among American Indian/Alaska Native communities and particularly among American Indian/Alaska Native women and infants call for immediate interventions to reach and offer syphilis testing to sexually active populations paired with timely treatment. Methods: The Great Plains Tribal Epidemiology Center within the Great Plains Tribal Leaders Health Board partnered with a local nontribal health care facility to offer free community-based syphilis testing in Rapid City, South Dakota, starting in December 2022 through June 2024. Participants received cash incentive cards for undergoing testing for syphilis, human immunodeficiency virus (HIV), and hepatitis C virus. Results: Fifteen community testing events were conducted. Laboratory-based syphilis testing was performed on 1434 unique individuals with an average age of 38.8 years. Seventy-six people were diagnosed with syphilis that had previously not been identified (prevalence, 5.3% [76 of 1434]; 51 [67.1%]) were female. Treatment was provided to 80.3% of people with syphilis (61 of 76) within an average of 36 days. In total, the 15 events cost $158,019 ($75,000 administrative staff time + $5100 laboratory staff time + $24,009 laboratory tests + $ 53,910 incentives) or $88 per test performed ($158,019 per 1797). The cost to identify a previously unidentified case was $2079 ($158,019 per 76 newly identified infected persons). Conclusions: This community-based screening event revealed high prevalence of undiagnosed syphilis. Incentives supported community members to access screening services. Collaborations between clinical, tribal, and public health entities to bring diagnosis and treatment services to patients using a community-based approach have clear benefits but need ongoing supportive resources to be maintained.- 10 July 2025
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 52 (12) , 775-779
Incentivized Community-Based Syphilis Screening: Uptake, Yield, and Cost
Background: High and increasing syphilis rates among American Indian/Alaska Native communities and particularly among American Indian/Alaska Native women and infants call for immediate interventions to reach and offer syphilis testing to sexually active populations paired with timely treatment. Methods: The Great Plains Tribal Epidemiology Center within the Great Plains Tribal Leaders Health Board partnered with a local nontribal health care facility to offer free community-based syphilis testing in Rapid City, South Dakota, starting in December 2022 through June 2024. Participants received cash incentive cards for undergoing testing for syphilis, human immunodeficiency virus (HIV), and hepatitis C virus. Results: Fifteen community testing events were conducted. Laboratory-based syphilis testing was performed on 1434 unique individuals with an average age of 38.8 years. Seventy-six people were diagnosed with syphilis that had previously not been identified (prevalence, 5.3% [76 of 1434]; 51 [67.1%]) were female. Treatment was provided to 80.3% of people with syphilis (61 of 76) within an average of 36 days. In total, the 15 events cost $158,019 ($75,000 administrative staff time + $5100 laboratory staff time + $24,009 laboratory tests + $ 53,910 incentives) or $88 per test performed ($158,019 per 1797). The cost to identify a previously unidentified case was $2079 ($158,019 per 76 newly identified infected persons). Conclusions: This community-based screening event revealed high prevalence of undiagnosed syphilis. Incentives supported community members to access screening services. Collaborations between clinical, tribal, and public health entities to bring diagnosis and treatment services to patients using a community-based approach have clear benefits but need ongoing supportive resources to be maintained.- 23 May 2024
- Published by SAGE Publications in Public Health Reports®
- Vol. 139 (6) , 734-743
Experience of Public Health Departments in Implementation of COVID-19 Case Investigation and Contact Tracing Programs
Objective: Case investigation and contact tracing (CI/CT) are fundamental public health efforts widely used during the COVID-19 pandemic to mitigate transmission. This study investigated how state, local, and tribal public health departments used CI/CT during the COVID-19 pandemic, including CI/CT methodology, staffing models, training and support, and efforts to identify or prioritize populations disproportionately affected by COVID-19. Methods: During March and April 2022, we conducted key informant interviews with up to 3 public health officials from 43 state, local, and tribal public health departments. From audio-recorded and transcribed interviews, we used the framework method to analyze key themes. Results: Major adjustments to CI/CT protocols during the pandemic included (1) prioritizing populations for outreach; (2) implementing automated outreach for nonprioritized groups, particularly during COVID-19 surges; (3) discontinuing contact tracing and focusing exclusively on case investigation; and (4) adding innovations to provide additional support. Key informants also discussed the utility of having backup staffing to support overwhelmed public health departments and spoke to the difficulty in “right-sizing” the public health workforce, with COVID-19 surges leaving public health departments understaffed as case rates rose and overstaffed as case rates fell. Conclusions: When addressing future epidemics or outbreaks, public health officials should consider strategies that improve the effectiveness of CI/CT efforts over time, such as prioritizing populations based on disproportionate risk, implementing automated outreach, developing models that provide flexible additional staffing resources as cases rise and fall among local public health departments, incorporating demographic data in laboratory reporting, providing community connections and support, and having a system of self-notification of contacts.
- 23 May 2024
- Published by SAGE Publications in Public Health Reports®
- Vol. 139 (6) , 734-743
Experience of Public Health Departments in Implementation of COVID-19 Case Investigation and Contact Tracing Programs
Objective: Case investigation and contact tracing (CI/CT) are fundamental public health efforts widely used during the COVID-19 pandemic to mitigate transmission. This study investigated how state, local, and tribal public health departments used CI/CT during the COVID-19 pandemic, including CI/CT methodology, staffing models, training and support, and efforts to identify or prioritize populations disproportionately affected by COVID-19. Methods: During March and April 2022, we conducted key informant interviews with up to 3 public health officials from 43 state, local, and tribal public health departments. From audio-recorded and transcribed interviews, we used the framework method to analyze key themes. Results: Major adjustments to CI/CT protocols during the pandemic included (1) prioritizing populations for outreach; (2) implementing automated outreach for nonprioritized groups, particularly during COVID-19 surges; (3) discontinuing contact tracing and focusing exclusively on case investigation; and (4) adding innovations to provide additional support. Key informants also discussed the utility of having backup staffing to support overwhelmed public health departments and spoke to the difficulty in “right-sizing” the public health workforce, with COVID-19 surges leaving public health departments understaffed as case rates rose and overstaffed as case rates fell. Conclusions: When addressing future epidemics or outbreaks, public health officials should consider strategies that improve the effectiveness of CI/CT efforts over time, such as prioritizing populations based on disproportionate risk, implementing automated outreach, developing models that provide flexible additional staffing resources as cases rise and fall among local public health departments, incorporating demographic data in laboratory reporting, providing community connections and support, and having a system of self-notification of contacts.
- 3 October 2023
- Published by Oxford University Press (OUP) in International Health
- Vol. 16 (3) , 279-282
Securing the supply of benzathine penicillin: a global perspective on risks and mitigation strategies to prevent future shortages
Benzathine benzylpenicillin is a globally indispensable medicine. As a long-lasting injectable penicillin, it serves as the primary treatment for syphilis, group A streptococcal infections, rheumatic fever and rheumatic heart disease. A competitive market and low profit margins, compounded by limited visibility of demand, have resulted in a decreased number of active pharmaceutical ingredient (API) manufacturers. By 2016, only three Chinese API manufacturers remained, continuing to supply to the global market today. Recurring global shortages, a consequence of supply and demand imbalances, indicate underlying market risks. Therefore, the need for mitigation strategies is imperative.
- 3 October 2023
- Published by Oxford University Press (OUP) in International Health
- Vol. 16 (3) , 279-282
Securing the supply of benzathine penicillin: a global perspective on risks and mitigation strategies to prevent future shortages
Benzathine benzylpenicillin is a globally indispensable medicine. As a long-lasting injectable penicillin, it serves as the primary treatment for syphilis, group A streptococcal infections, rheumatic fever and rheumatic heart disease. A competitive market and low profit margins, compounded by limited visibility of demand, have resulted in a decreased number of active pharmaceutical ingredient (API) manufacturers. By 2016, only three Chinese API manufacturers remained, continuing to supply to the global market today. Recurring global shortages, a consequence of supply and demand imbalances, indicate underlying market risks. Therefore, the need for mitigation strategies is imperative.
- Open Access
- 30 May 2023
- Published by Wiley in Nursing Open
- Vol. 10 (11) , 7437-7445
Evaluation of the impact of guideline communication from the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services among US healthcare providers: COVID‐19 prevention counselling guidance
AimTo evaluate healthcare provider awareness and uptake of the Centers for Medicare & Medicaid Services (CMS) billing for coronavirus disease 2019 (COVID-19) prevention counselling and the delivery of prevention counselling to patients awaiting severe acute respiratory syndrome coronavirus 2 test results. DesignCross sectional survey of US-based healthcare providers in February 2021. MethodsAnalysis of associations with healthcare provider-reported awareness of CMS prevention counselling guidance and billing with provider type, specialty, and work setting. ResultsA total of 1919 healthcare providers responded to the survey. Overall, 38% (726/1919) of providers reported awareness of available CMS reimbursement for COVID-19 patient counselling and 29% (465/1614) of CMS billing-eligible providers reported billing for this counselling. Among physicians, those aware of CMS guidance were significantly more likely to bill (58%) versus those unaware (10%). Among RNSights respondents eligible for CMS billing (n = 114), 31% of those aware of the guidance reported billing as compared to 0% of those not aware.
- 30 May 2023
- Published by Wiley in Nursing Open
- Vol. 10 (11) , 7437-7445
Open AccessEvaluation of the impact of guideline communication from the Centers for Disease Control and Prevention and the Centers for Medicare and Medicaid Services among US healthcare providers: COVID‐19 prevention counselling guidance
AimTo evaluate healthcare provider awareness and uptake of the Centers for Medicare & Medicaid Services (CMS) billing for coronavirus disease 2019 (COVID-19) prevention counselling and the delivery of prevention counselling to patients awaiting severe acute respiratory syndrome coronavirus 2 test results. DesignCross sectional survey of US-based healthcare providers in February 2021. MethodsAnalysis of associations with healthcare provider-reported awareness of CMS prevention counselling guidance and billing with provider type, specialty, and work setting. ResultsA total of 1919 healthcare providers responded to the survey. Overall, 38% (726/1919) of providers reported awareness of available CMS reimbursement for COVID-19 patient counselling and 29% (465/1614) of CMS billing-eligible providers reported billing for this counselling. Among physicians, those aware of CMS guidance were significantly more likely to bill (58%) versus those unaware (10%). Among RNSights respondents eligible for CMS billing (n = 114), 31% of those aware of the guidance reported billing as compared to 0% of those not aware.
- Open Access
- 29 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0001252
Travel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020—February 2021
The first three SARS-CoV-2 phylogenetic lineages classified as variants of concern (VOCs) in the United States (U.S.) from December 15, 2020 to February 28, 2021, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) lineages, were initially detected internationally. This investigation examined available travel history of coronavirus disease 2019 (COVID-19) cases reported in the U.S. in whom laboratory testing showed one of these initial VOCs. Travel history, demographics, and health outcomes for a convenience sample of persons infected with a SARS-CoV-2 VOC from December 15, 2020 through February 28, 2021 were provided by 35 state and city health departments, and proportion reporting travel was calculated. Of 1,761 confirmed VOC cases analyzed, 1,368 had available data on travel history. Of those with data on travel history, 1,168 (85%) reported no travel preceding laboratory confirmation of SARS-CoV-2 and only 105 (8%) reported international travel during the 30 days preceding a positive SARS-CoV-2 test or symptom onset. International travel was reported by 92/1,304 (7%) of persons infected with the Alpha variant, 7/55 (22%) with Beta, and 5/9 (56%) with Gamma. Of the first three SARS-CoV-2 lineages designated as VOCs in the U.S., international travel was common only among the few Gamma cases. Most persons infected with Alpha and Beta variant reported no travel history, therefore, community transmission of these VOCs was likely common in the U.S. by March 2021. These findings underscore the importance of global surveillance using whole genome sequencing to detect and inform mitigation strategies for emerging SARS-CoV-2 VOCs.
- 29 March 2023
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 3 (3) , e0001252
Open AccessTravel history among persons infected with SARS-CoV-2 variants of concern in the United States, December 2020—February 2021
The first three SARS-CoV-2 phylogenetic lineages classified as variants of concern (VOCs) in the United States (U.S.) from December 15, 2020 to February 28, 2021, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) lineages, were initially detected internationally. This investigation examined available travel history of coronavirus disease 2019 (COVID-19) cases reported in the U.S. in whom laboratory testing showed one of these initial VOCs. Travel history, demographics, and health outcomes for a convenience sample of persons infected with a SARS-CoV-2 VOC from December 15, 2020 through February 28, 2021 were provided by 35 state and city health departments, and proportion reporting travel was calculated. Of 1,761 confirmed VOC cases analyzed, 1,368 had available data on travel history. Of those with data on travel history, 1,168 (85%) reported no travel preceding laboratory confirmation of SARS-CoV-2 and only 105 (8%) reported international travel during the 30 days preceding a positive SARS-CoV-2 test or symptom onset. International travel was reported by 92/1,304 (7%) of persons infected with the Alpha variant, 7/55 (22%) with Beta, and 5/9 (56%) with Gamma. Of the first three SARS-CoV-2 lineages designated as VOCs in the U.S., international travel was common only among the few Gamma cases. Most persons infected with Alpha and Beta variant reported no travel history, therefore, community transmission of these VOCs was likely common in the U.S. by March 2021. These findings underscore the importance of global surveillance using whole genome sequencing to detect and inform mitigation strategies for emerging SARS-CoV-2 VOCs.